Clinical Trial Update: A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating multiple therapies in biomarker-selected participants with resectable stage IB-III non-small cell lung cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING